Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 12, 2024European Journal of NeurologyOpen Access

Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life

View Full Paper
Ask AI
Bookmark
Share

Authors

URUwe ReuterUniversitätsmedizin GreifswaldAHAxel HeinzeSchmerzklinik KielAGAstrid GendollaPraxis

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Reuter et al. (2024) studied this question.

synapsesocial.com/papers/68e5ca68b6db64358756066ahttps://doi.org/10.1111/ene.16437
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study ( IBMS‐II )2013 · 392 citations
  2. 2Topiramate in Migraine Prevention2004 · 532 citations
  3. 3Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update2024 · 228 citations
  4. 4Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study2021 · 26 citations
  5. 5Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study2021 · 52 citations